“…As more patients present with early stage disease, the prediction of lymph node involvement requires a tool with more precision within this group. Therefore, although Hayes et al express concern that we exclude cT3 disease and prostate-specific antigen (PSA) values .26, they highlight an important point: in the era of Radiation Therapy Oncology Group 9413 and the RF, these findings were more commonplace (5-6% of patients) (3,6), whereas in the contemporary era, these findings are so rare that the most recent version of the Partin tables excludes these patients (3). Our approach is therefore consistent with that employed in these revised Partin tables.…”